Plasma Chemokines CXCL10 and CXCL9 As Potential Diagnostic Markers of Drug-sensitive and Drug-resistant Tuberculosis

Overview

Journal Sci Rep

Specialty Science

Date 2023 May 6

PMID 37149713

Authors

Pavithra Sampath

Anuradha Rajamanickam

Kannan Thiruvengadam

Alangudi Palaniappan Natarajan

Syed Hissar

Madhavan Dhanapal

Bharathiraja Thangavelu

Lavanya Jayabal

Paranchi Murugesan Ramesh

Uma Devi Ranganathan

Subash Babu

Ramalingam Bethunaickan

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) diagnosis still remains to be a challenge with the currently used immune based diagnostic methods particularly Interferon Gamma Release Assay due to the sensitivity issues and their inability in differentiating stages of TB infection. Immune markers are valuable sources for understanding disease biology and are easily accessible. Chemokines, the stimulant, and the shaper of host immune responses are the vital hub for disease mediated dysregulation and their varied levels in TB disease are considered as an important marker to define the disease status. Hence, we wanted to examine the levels of chemokines among the individuals with drug-resistant, drug-sensitive, and latent TB compared to healthy individuals. Our results demonstrated that the differential levels of chemokines between the study groups and revealed that CXCL10 and CXCL9 as potential markers of drug-resistant and drug-sensitive TB with better stage discriminating abilities.

Citing Articles

The importance of inflammatory biomarkers in detecting and managing latent tuberculosis infection.

Gunasekaran H, Ranganathan U, Bethunaickan R Front Immunol. 2025; 16:1538127.

PMID: 39981231 PMC: 11839662. DOI: 10.3389/fimmu.2025.1538127.

The role of antibiotic-derived mycobacterial vesicles in tuberculosis pathogenesis.

Davids C, Umashankar-Rao K, Kassaliete J, Ahmadi S, Happonen L, Welinder C Sci Rep. 2024; 14(1):28198.

PMID: 39548211 PMC: 11568285. DOI: 10.1038/s41598-024-79215-3.

Transcriptomics-based anti-tuberculous mechanism of traditional Chinese polyherbal preparation NiuBeiXiaoHe intermediates.

Wang N, Ma Q, Zhang J, Wang J, Li X, Liang Y Front Pharmacol. 2024; 15:1415951.

PMID: 39364045 PMC: 11446850. DOI: 10.3389/fphar.2024.1415951.

CXCL9/CXCL10 as biomarkers the monitoring of treatment responses in Pulmonary TB patients: a systematic review and meta-analysis.

Wei Z, Chen Y, Dong P, Liu Z, Lai X, Wang N BMC Infect Dis. 2024; 24(1):1037.

PMID: 39333908 PMC: 11428339. DOI: 10.1186/s12879-024-09939-0.

Inflammatory immune profiles associated with disease severity in pulmonary tuberculosis patients with moderate to severe clinical TB or anemia.

Ashenafi S, Loreti M, Bekele A, Aseffa G, Amogne W, Kassa E Front Immunol. 2024; 14:1296501.

PMID: 38162636 PMC: 10756900. DOI: 10.3389/fimmu.2023.1296501.

References

Nouailles G, Dorhoi A, Koch M, Zerrahn J, Weiner 3rd J, Fae K . CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis. J Clin Invest. 2014; 124(3):1268-82. PMC: 3934185. DOI: 10.1172/JCI72030. View

Fan J, Yang Y, Wang L, Shang X, Zhang L, Sun H . Study on the Correlation between Interleukin-27 and CXCL10 in Pulmonary Tuberculosis. J Immunol Res. 2022; 2022:2932837. PMC: 9242752. DOI: 10.1155/2022/2932837. View

Feng W, Flores-Villanueva P, Mokrousov I, Wu X, Xiao J, Jiao W . CCL2−2518 (A/G) polymorphisms and tuberculosis susceptibility: a meta-analysis. Int J Tuberc Lung Dis. 2011; 16(2):150-6. DOI: 10.5588/ijtld.11.0205. View

Abubakar I, Stagg H, Whitworth H, Lalvani A . How should I interpret an interferon gamma release assay result for tuberculosis infection?. Thorax. 2013; 68(3):298-301. PMC: 5741174. DOI: 10.1136/thoraxjnl-2013-203247. View

Kahnert A, Hopken U, Stein M, Bandermann S, Lipp M, Kaufmann S . Mycobacterium tuberculosis triggers formation of lymphoid structure in murine lungs. J Infect Dis. 2006; 195(1):46-54. DOI: 10.1086/508894. View

Ali Z, Mankhi A, Adhiah A . Significance of the chemokine CXCL10 and human beta-defensin-3 as biomarkers of pulmonary tuberculosis. Tuberculosis (Edinb). 2021; 128:102078. DOI: 10.1016/j.tube.2021.102078. View

Shang X, Wang L, Liu Y, Liu X, Lv J, Zhou X . Diagnostic value of CXCR3 and its ligands in spinal tuberculosis. Exp Ther Med. 2020; 21(1):73. PMC: 7716639. DOI: 10.3892/etm.2020.9505. View

Wergeland I, Pullar N, Assmus J, Ueland T, Tonby K, Feruglio S . IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy. J Infect. 2015; 70(4):381-91. DOI: 10.1016/j.jinf.2014.12.019. View

Guerreiro R, Santos-Costa Q, Azevedo-Pereira J . [The chemokines and their receptors: characteristics and physiological functions]. Acta Med Port. 2012; 24 Suppl 4:967-76. View

10.

Wawrocki S, Seweryn M, Kielnierowski G, Rudnicka W, Wlodarczyk M, Druszczynska M . IL-18/IL-37/IP-10 signalling complex as a potential biomarker for discriminating active and latent TB. PLoS One. 2019; 14(12):e0225556. PMC: 6903724. DOI: 10.1371/journal.pone.0225556. View

11.

Sampath P, Rajamanickam A, Thiruvengadam K, Natarajan A, Hissar S, Dhanapal M . Cytokine upsurge among drug-resistant tuberculosis endorse the signatures of hyper inflammation and disease severity. Sci Rep. 2023; 13(1):785. PMC: 9842614. DOI: 10.1038/s41598-023-27895-8. View

12.

Palucci I, Battah B, Salustri A, De Maio F, Petrone L, Ciccosanti F . IP-10 contributes to the inhibition of mycobacterial growth in an ex vivo whole blood assay. Int J Med Microbiol. 2019; 309(5):299-306. DOI: 10.1016/j.ijmm.2019.05.005. View

13.

Sheng Y, Qi Q . Association of chemotactic chemokine ligand 5 rs2107538 polymorphism with tuberculosis susceptibility: A meta-analysis. Innate Immun. 2019; 26(5):358-363. PMC: 7903532. DOI: 10.1177/1753425919891662. View

14.

Tsenova L, Singhal A . Effects of host-directed therapies on the pathology of tuberculosis. J Pathol. 2020; 250(5):636-646. DOI: 10.1002/path.5407. View

15.

Joosten S, van Meijgaarden K, Arend S, Prins C, Oftung F, Korsvold G . Mycobacterial growth inhibition is associated with trained innate immunity. J Clin Invest. 2018; 128(5):1837-1851. PMC: 5919803. DOI: 10.1172/JCI97508. View

16.

Kumar N, Hissar S, Thiruvengadam K, Banurekha V, Balaji S, Elilarasi S . Plasma chemokines as immune biomarkers for diagnosis of pediatric tuberculosis. BMC Infect Dis. 2021; 21(1):1055. PMC: 8504024. DOI: 10.1186/s12879-021-06749-6. View

17.

Ferrian S, Manca C, Lubbe S, Conradie F, Ismail N, Kaplan G . A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis. PLoS One. 2017; 12(5):e0176660. PMC: 5413057. DOI: 10.1371/journal.pone.0176660. View

18.

Hilda J, Narasimhan M, Das S . Neutrophils from pulmonary tuberculosis patients show augmented levels of chemokines MIP-1α, IL-8 and MCP-1 which further increase upon in vitro infection with mycobacterial strains. Hum Immunol. 2014; 75(8):914-22. DOI: 10.1016/j.humimm.2014.06.020. View

19.

Alessandri A, Souza A, Oliveira S, Macedo G, Teixeira M, Teixeira A . Concentrations of CXCL8, CXCL9 and sTNFR1 in plasma of patients with pulmonary tuberculosis undergoing treatment. Inflamm Res. 2006; 55(12):528-33. DOI: 10.1007/s00011-006-5136-9. View

20.

Mihret A, Bekele Y, Bobosha K, Kidd M, Aseffa A, Howe R . Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection. J Infect. 2012; 66(4):357-65. DOI: 10.1016/j.jinf.2012.11.005. View